Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag combined with prednisone for adult primary immune thrombocytopenia
ChiCTR2600134526Phase 2Completed
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Mar 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag and prednisone in immune thrombocytopenia (ITP), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Proportion of patients with sustained effectiveness after 26 weeks of treatment. Started Mar 2024; status: completed.
02
Drugs
hetrombopagprednisone
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2600134526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134526.